|
|||||
|
|
Retroperitoneal Lymphadenectomy for High Risk,Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial |
|
| Authors: | Benjamin T. Ristau Judi Manola Naomi B. Haas Daniel Y.C. Heng Edward M. Messing Christopher G. Wood Christopher J. Kane Robert S. DiPaola Robert G. Uzzo |
| Affiliation: | 1. Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania;2. Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pennsylvania;3. ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, Massachusetts;4. Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada;5. Department of Urology, University of Rochester, Rochester, New York;6. University of Texas M. D. Anderson Cancer Center, Houston, Texas;g. Moores Cancer Center, University of California-San Diego, La Jolla, California;h. Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey |
| Abstract: | |
| Keywords: | kidney carcinoma renal cell lymph node excision chemotherapy adjuvant mortality ACRIN American College of Radiology Imaging Network AJCC American Joint Committee on Cancer ASSURE Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma CCOP Community Cancer Oncology Program DFS disease-free survival ECOG Eastern Cooperative Oncology Group EORTC European Organisation for Research and Treatment of Cancer LND lymph node dissection OS overall survival RCC renal cell carcinoma |
| 本文献已被 ScienceDirect 等数据库收录！ | |